Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lymphomas

Clinical Trial at: Compass Oncology - Portland

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

  • Details

ClinicalTrials.gov ID: NCT03646123
Diagnosis Type: Hodgkins
USOR Number: 18013

  • Practice Details

265 North Broadway
Portland, Oregon 97227
P: (503) 280-1223

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Portland

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

  • Details

ClinicalTrials.gov ID: NCT03646123
Diagnosis Type: Hodgkins
USOR Number: 18013

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, Oregon 97213
P: (503) 239-7767

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Tigard

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

  • Details

ClinicalTrials.gov ID: NCT03646123
Diagnosis Type: Hodgkins
USOR Number: 18013

  • Practice Details

12123 SW 69th Avenue
Tigard, Oregon 97223
P: (971) 708.7600

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Vancouver

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

  • Details

ClinicalTrials.gov ID: NCT03646123
Diagnosis Type: Hodgkins
USOR Number: 18013

  • Practice Details

210 SE 136th Ave
Vancouver, Washington 98684
P: (360) 944-9889

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Portland

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, Oregon 97213
P: (503) 239-7767

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Tigard

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

12123 SW 69th Avenue
Tigard, Oregon 97223
P: (971) 708.7600

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Vancouver

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

210 SE 136th Ave
Vancouver, Washington 98684
P: (360) 944-9889

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Portland

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

265 North Broadway
Portland, Oregon 97227
P: (503) 280-1223

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Portland

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

265 North Broadway
Portland, Oregon 97227
P: (503) 280-1223

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Portland

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, Oregon 97213
P: (503) 239-7767

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Tigard

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

12123 SW 69th Avenue
Tigard, Oregon 97223
P: (971) 708.7600

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Vancouver

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

210 SE 136th Ave
Vancouver, Washington 98684
P: (360) 944-9889

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Tigard

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205)

  • Details

ClinicalTrials.gov ID: NCT02793583
Diagnosis Type: Non-Hodgkins
USOR Number: 16065

  • Practice Details

12123 SW 69th Avenue
Tigard, Oregon 97223
P: (971) 708.7600

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Portland

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205)

  • Details

ClinicalTrials.gov ID: NCT02793583
Diagnosis Type: Non-Hodgkins
USOR Number: 16065

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, Oregon 97213
P: (503) 239-7767

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Vancouver

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205)

  • Details

ClinicalTrials.gov ID: NCT02793583
Diagnosis Type: Non-Hodgkins
USOR Number: 16065

  • Practice Details

210 SE 136th Ave
Vancouver, Washington 98684
P: (360) 944-9889

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Portland

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205)

  • Details

ClinicalTrials.gov ID: NCT02793583
Diagnosis Type: Non-Hodgkins
USOR Number: 16065

  • Practice Details

265 North Broadway
Portland, Oregon 97227
P: (503) 280-1223

More Details View Practice Page